[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100618548":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":43,"responsibleParty":59,"collaborators":63,"id":90,"slug":91,"hasResults":92,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":26,"eligibilityCriteria":96,"healthyVolunteers":92,"sex":97,"minAge":98,"maxAge":26,"enrollmentInfo":99,"targetDuration":26,"studyType":102,"phases":103,"briefSummary":105,"conditions":106,"keywords":108,"overallStatus":46,"whyStopped":26,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":125},{"fullName":5,"class":6},"Guang'anmen Hospital of China Academy of Chinese Medical Sciences","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"TAIC Group","EXPERIMENTAL","Patients in the TAIC group will receive FOLFOX-based TAIC at Week 0 and Week 4 and receive FOLFOX-based IVC at Week 2 and Week 6. The FOLFOX-based TAIC consists of oxaliplatin (85 mg\u002Fm²) and leucovorin (400 mg\u002Fm²), each administered as a 2-hour transarterial infusion, and fluorouracil (2400 mg\u002Fm²) administered as a 44-hour continuous transarterial infusion. Before placing a microcatheter into the feeding artery of the CRC, transarterial chemoembolization is performed for the liver metastases in patients with CRLM. The iodized oil emulsion is prepared by mixing 4 mL of iodized oil with 20 mg of oxaliplatin powder. Through the microcatheter, 0.5 mL of the iodized oil emulsion is slowly injected into the liver tumors via the feeding arterial branches. The technical endpoint of embolization is the absence of additional tumor staining or stasis\u002Fnear stasis of the tumor-feeding arteries. The IVC and targeted therapy regimens are the same as those in the IVC group.",[13],"Procedure: Transarterial infusion chemotherapy (TAIC)",{"label":15,"type":16,"description":17,"interventionNames":18},"IVC group","ACTIVE_COMPARATOR","Patients in the IVC group will receive FOLFOX-based IVC every 2 weeks for a total duration of 8 weeks. The FOLFOX regimen consists of oxaliplatin (85 mg\u002Fm²) and leucovorin (400 mg\u002Fm²), each administered as a 2-hour intravenous infusion, and fluorouracil (2400 mg\u002Fm²) administered as a 44-hour continuous intravenous infusion. For patients with CRLM, targeted therapy will be selected according to RAS\u002FBRAF status and primary tumor side. Cetuximab will be administered by intravenous injection for the treatment of RAS\u002FBRAF wild-type left-sided CRLM. Bevacizumab will be administered by intravenous injection for the treatment of RAS\u002FBRAF wild-type right-sided CRLM and RAS\u002FBRAF mutant CRLM irrespective of primary tumor location.",[19],"Procedure: Intravenous Chemotherapy（IVC）",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"PROCEDURE","Transarterial infusion chemotherapy (TAIC)","TAIC can increase the local intra-tumoral concentrations of chemotherapeutic agents by intensifying drug delivery into the tumor via super-selective catheterization of the tumor-feeding artery, and meanwhile reduce systematic toxicity.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Intravenous Chemotherapy（IVC）","Intravenous administration of chemotherapeutic agents is the mainstay of chemotherapy.",[15],[32],{"name":33,"affiliation":5,"role":34},"Quanda Liu, MD","PRINCIPAL_INVESTIGATOR",[36,41],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},"Quanda Liu Chief physician, MD","CONTACT","01088001037","hnzyydxwjp@163.com",{"name":42,"role":38,"phone":26,"phoneExt":26,"email":40},"Junpeng Wang, MD",[44],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":26,"geoPoint":26,"contacts":52},"Guang'anmen Hospital, China Academy of Chinese Medical Sciences","RECRUITING","Xicheng","Beijing Municipality","100053","China","CN",[53,54,55,57],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},{"name":26,"role":38,"phone":26,"phoneExt":26,"email":40},{"name":56,"role":34,"phone":26,"phoneExt":26,"email":26},"Liuxin Duan, MD",{"name":58,"role":34,"phone":26,"phoneExt":26,"email":26},"Li Yao, MD",{"type":60,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"SPONSOR_INVESTIGATOR","Quanda Liu","Chief physician",[64,66,69,71,73,76,78,80,82,84,86,88],{"name":65,"class":6},"Liaoning Cancer Hospital & Institute",{"name":67,"class":68},"The Rocket Force Characteristic Medical Center","UNKNOWN",{"name":70,"class":6},"Second Affiliated Hospital of Nanchang University",{"name":72,"class":6},"Affiliated Hospital of Hebei University",{"name":74,"class":75},"The First Hospital of Qinhuangdao","OTHER_GOV",{"name":77,"class":68},"The Central Hospital of Handan City",{"name":79,"class":68},"The First People's Hospital of Jiujiang City",{"name":81,"class":6},"Changzhi Medical College",{"name":83,"class":68},"Zibo Boshan District Traditional Chinese Medicine Hospital",{"name":85,"class":68},"Hebei Yixian Hospital",{"name":87,"class":68},"Baoding Mancheng District People's Hospital",{"name":89,"class":68},"The Shanghai Yangpu Central Hospital","100618548","clinical-efficacy-of-transarterial-infusion-chemotherapy-for-unresectable-colorectal-cancer-100618548",false,"NCT07333053","Clinical Efficacy of Transarterial Infusion Chemotherapy for Unresectable Colorectal Cancer","FOLFOX-Based Transarterial Infusion Chemotherapy for Unresectable Colorectal Cancer: Protocol of an Open-Label, Multicentre, Randomised, Controlled, Phase Ⅱ Trial","Study population:\n\nPatients who meet all inclusion criteria and none of the exclusion criteria are eligible for enrolment and study treatment.\n\nInclusion criteria:\n\n1. Age ≥ 18 years old;\n2. Histopathologically confirmed CRC adenocarcinoma;\n3. Locally advanced CRC confirmed as clinical T4 stage on CT\u002FMRI imaging, with or without synchronous liver metastases;\n4. For patients with CRLM, hepatic tumor burden shall be lower than the burden of the primary colorectal lesion. Consequently, the multidisciplinary team (MDT) agree by consensus that CRC should be a priority target for treatment.\n5. No prior administration of chemotherapy, targeted therapy or radiotherapy for the current malignancy;\n6. Adequate haematological, heart, liver and renal functions are required, with the following specific criteria: white blood cell count≥4×109 \u002FL, neutrophils≥1.5×109 \u002FL, platelets≥100×10⁹ \u002FL, haemoglobin≥100 g\u002FL, total bilirubin≤34.2 μmol\u002FL, aspartate aminotransferase≤100 IU\u002FL, alanine aminotransferase≤100 IU\u002FL, serum creatinine ≤133 μmol\u002FL or creatinine clearance rate≥60 mL\u002Fmin, and urine protein\u002Fcreatinine\\\u003C1;\n7. Estimated survival is more than 3 months;\n8. Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 2;\n9. All the patients in this study are required to sign an informed consent form.\n\nExclusion criteria:\n\n1. Patients have other primary malignant tumors;\n2. Patients with recurrent CRC;\n3. Patients with distant metastases besides synchronous hepatic metastases (e.g., pulmonary, bone, or brain metastases);\n4. For patients with CRLM, the MDT consensus recommends a liver-first treatment strategy to avoid the risk of rapid hepatic lesion progression;\n5. CRC patients with gastrointestinal perforation\n6. Patients with malignant bowel obstruction refractory to conservative management;\n7. Patients are allergic to the antitumor agents;\n8. Women pregnant, breastfeeding or planning to become pregnant;\n9. Patients receiving other antitumor therapies, such as chemotherapy, targeted therapy or radiotherapy;\n10. Patients with MSI-H\u002FdMMR CRC.","ALL","18 Years",{"count":100,"type":101},50,"ESTIMATED","INTERVENTIONAL",[104],"NA","This is a prospective, multicenter, randomized, open-label clinical trial. It aims to investigate whether intensive transarterial infusion chemotherapy (TAIC) followed by sequential intravenous chemotherapy (IVC) is clinically more effective than IVC alone in the treatment of unresectable colorectal cancer (uCRC).",[107],"Unresectable Colorectal Cancer",[109,110,111,112,113,114,115],"Transarterial Infusion Chemotherapy","Bevacizumab","Cetuximab","Colorectal Cancer","FOLFOX Protocol","Unresectable","Clinical Trial","2026-08-12",{"date":118,"type":119},"2026-08-14","ACTUAL",{"date":121,"type":119},"2026-03-20",{"date":123,"type":101},"2027-12-31",{"name":61,"class":6},1]